

EXHIBIT S23 TO DECLARATION OF  
STEPHEN G. SCHWARZ IN SUPPORT OF  
PLAINTIFFS' MOTION FOR CLASS  
CERTIFICATION



E. I. DU PONT DE NEMOURS & COMPANY  
WILMINGTON, DELAWARE 19898

LEGAL DEPARTMENT

cc: P. M. Norling, Adm.  
S. N. Boyd, Jr., CD&P Dept.  
B. W. Karrh, M.D., Empl. Rel. De  
E. D. Champney, Jr., PP&R Dept.  
J. W. Raines, PP&R Dept.  
R. M. Shepherd, PP&R Dept.  
A. A. Wright, Textile Fibers Dep  
B. C. McKusick, CR&D Dept., Hasl

RECEIVED

AUG 01 1979

BRUCE W. KARRH, MD

July 30, 1979

TO: FILE

FROM: EUGENE BERMAN

FLUORINE BLOOD LEVELS

A meeting, attended by the above individuals, was held on July 23, 1979 to review additional PPSR information related to its use of ammonium perfluoro octanoate (3M's product FC-143). The discussion included a review of (1) data provided by 3M Company, including fluorine levels in blood and urine measured in 3M employees exposed to FC-143 and data on fluorine blood levels in the general population, (2) fluorine blood levels measured in eight PP&R Washington Works employees, as well as levels measured in 55 CD&P Chambers Works employees, and (3) available health data.

Based upon this review, it was concluded that the information did not reasonably support a conclusion that a substantial risk was presented, primarily based upon the absence of any known adverse health effects related to fluorine in blood. Accordingly, it was concluded that no reporting under TSCA Section 8(e) was required. Corporate Medical Division will continue its review of the Washington Works employees' medical data to confirm that there are no adverse health effects.

On July 26, 1979, I advised Robert Prokop of 3M of our above conclusions with regard to Section 8(e) and our general practice of reporting or otherwise publicizing relevant findings even if they are not required to be reported under Section 8(e). I asked Prokop to clarify what plans 3M had with regard to publicizing this fluorine blood level information and/or directly advising the relevant health agency of this information. Prokop indicated that he believed 3M was favorably disposed toward disclosing this information and promised a more definitive response next week after reviewing the matter with Lester Krogh (3M's Division Vice President).

EB/caw

EID107196

000165

RL001777